Cyclic Peptide
Intracellular Protein-Protein Interactions (PPIs) are tough targets for both small molecules and antibody drugs, while conventional peptides are neither orally available nor cell-permeable. With advanced biotechnology and chemistry, we successfully established a proprietary library of orally available and cell-permeable cyclic peptides and screening technology. Our first mid-size molecule drug, LUNA18, is being tested in clinical studies, and we have multiple cyclic peptide projects in the drug discovery stage.
